VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA’s lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA’s pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation.
-
Companies To Watch
ACCP.OB 1.28 -0.04
ALXA 0.51 -0.02
ARDM.OB 0.14 +0.015
CGNH.OB 0.46 +0.02
CNDO 6.85 +0.07
CRMD 0.36 +0.0099
DARA 2.13 -0.23
DND.TO 1.03 -0.20
DVAX 4.04 -0.09
GLPG.BR 11.48 +0.03
KERX 3.04 -0.01
LPTN.OB 0.8411 -0.0789
MEDW 14.51 -0.37
PBIO 0.73 +0.03
RPBC.PK 0.004 0.00
SNWV.OB 0.40 -0.05
SYN 2.36 -0.19
THLD 6.03 +1.02
VTUS 9.47 +0.04
XXII.OB 0.401 -0.189
ZIOP 4.90 -0.11
2012-02-22 15:36
